Evidence map›Paper›PMID 23550061›Full record

ArticleDatabase : the journal of biological databases and curation2013

curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome.

Benjamin Frederick Ganzfried, Markus Riester, Benjamin Haibe-Kains, Thomas Risch, Svitlana Tyekucheva, Ina Jazic, Xin Victoria Wang, Mahnaz Ahmadifar, Michael J Birrer, Giovanni Parmigiani and 2 more

Abstract read
In one paragraph

Article in Database : the journal of biological databases and curation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

114 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Outcome-Adaptive Lasso for Cox Proportional Hazards Model.Biometrical journal. Biometrische Zeitschrift · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Two-stage sampling for better survival model performance.BMC medical research methodology · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Fast Variational Inference for Bayesian Factor Analysis in Single and Multi-Study Settings.Journal of computational and graphical statistics : a joint publication of American Statistical Association, Institute of Mathematical Statistics, Interface Foundation of North America · 2025
    Article
  18. Article
  19. Article
  20. Molecular Subtypes of High-Grade Serous Ovarian Cancer across Racial Groups and Gene Expression Platforms.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024
    Article

54 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Benjamin Frederick GanzfriedDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Markus Riester
Benjamin Haibe-Kains
Thomas Risch
Svitlana Tyekucheva
Ina Jazic
Xin Victoria Wang
Mahnaz Ahmadifar
Michael J Birrer
Giovanni Parmigiani
Curtis Huttenhower
Levi Waldron

Funding

Genomic Stratification of Ovarian Cancer PatientsRC4CA156551 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BIRRER, MICHAEL · 2010 to 2010
$3.7M
NCI NIH HHS 1RC4CA156551-01
6 · The paper itself

Abstract

This article introduces a manually curated data collection for gene expression meta-analysis of patients with ovarian cancer and software for reproducible preparation of similar databases. This resource provides uniformly prepared microarray data for 2970 patients from 23 studies with curated and documented clinical metadata. It allows users to efficiently identify studies and patient subgroups of interest for analysis and to perform meta-analysis immediately without the challenges posed by harmonizing heterogeneous microarray technologies, study designs, expression data processing methods and clinical data formats. We confirm that the recently proposed biomarker CXCL12 is associated with patient survival, independently of stage and optimal surgical debulking, which was possible only through meta-analysis owing to insufficient sample sizes of the individual studies. The database is implemented as the curatedOvarianData Bioconductor package for the R statistical computing language, providing a comprehensive and flexible resource for clinically oriented investigation of the ovarian cancer transcriptome. The package and pipeline for producing it are available from http://bcb.dfci.harvard.edu/ovariancancer.

Indexed as

Databases, GeneticMolecular Sequence AnnotationChemokine CXCL12Chromosome MappingData MiningFemaleGene Expression Regulation, NeoplasticHumansOvarian NeoplasmsSoftware DesignSurvival AnalysisTranscriptomeChemokine CXCL12CXCL12 protein, human

Identifiers

PMID23550061
PMCPMC3625954

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.